Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Has announcements × Pancreatic Neoplasms × olaparib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Ovarian Neoplasms 4 Breast Neoplasms 2 Pathologic Complete Response 1 Pancreatic Neoplasms 1 Neoplasm Metastasis 1 Metastatic Castration-resistant Prostate Cancer 1 Fanconi Anemia, Complementation Group D1 1 Endometrial Neoplasms 1

Interventions

zenocutuzumab 1 trastuzumab deruxtecan 1 sacituzumab govitecan 1 pembrolizumab 1 olaparib 1 entrectinib 1 adagrasib 1 Cetuximab 1 Afatinib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02184195 2023-09-13

POLO

AstraZeneca

Phase 3 Completed

154 enrolled 20 charts 1 FDA

Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡